CN1056605C - 作为人速激肽ⅲ受体的选择性拮抗剂的化合物及其用途 - Google Patents
作为人速激肽ⅲ受体的选择性拮抗剂的化合物及其用途 Download PDFInfo
- Publication number
- CN1056605C CN1056605C CN95103542A CN95103542A CN1056605C CN 1056605 C CN1056605 C CN 1056605C CN 95103542 A CN95103542 A CN 95103542A CN 95103542 A CN95103542 A CN 95103542A CN 1056605 C CN1056605 C CN 1056605C
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- phenylpiperidine
- dichlorophenyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Description
实施例序号 | R2 | -T-A-Z- | m.p.℃ |
14 | -OCOC2H5 | -COOCH2C6H5 | 86 |
Claims (13)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9403193 | 1994-03-18 | ||
FR9403193A FR2717477B1 (fr) | 1994-03-18 | 1994-03-18 | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
FR9409478A FR2717478B1 (fr) | 1994-03-18 | 1994-07-29 | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
FR9409478 | 1994-07-29 | ||
FR9500571A FR2719311B1 (fr) | 1994-03-18 | 1995-01-19 | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
FR9500571 | 1995-01-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1128756A CN1128756A (zh) | 1996-08-14 |
CN1056605C true CN1056605C (zh) | 2000-09-20 |
Family
ID=27252886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95103542A Expired - Fee Related CN1056605C (zh) | 1994-03-18 | 1995-03-17 | 作为人速激肽ⅲ受体的选择性拮抗剂的化合物及其用途 |
Country Status (23)
Country | Link |
---|---|
US (3) | US5942523A (zh) |
EP (1) | EP0673928B1 (zh) |
JP (1) | JP2922816B2 (zh) |
KR (1) | KR100238343B1 (zh) |
CN (1) | CN1056605C (zh) |
AT (1) | ATE204863T1 (zh) |
AU (1) | AU693845B2 (zh) |
CA (1) | CA2145000C (zh) |
CY (1) | CY2278B1 (zh) |
DE (1) | DE69522355T2 (zh) |
DK (1) | DK0673928T3 (zh) |
ES (1) | ES2164746T3 (zh) |
FI (1) | FI116621B (zh) |
FR (1) | FR2719311B1 (zh) |
HK (1) | HK1005137A1 (zh) |
HU (1) | HUT72065A (zh) |
IL (1) | IL113026A (zh) |
NO (2) | NO302944B1 (zh) |
NZ (1) | NZ270727A (zh) |
PL (1) | PL185075B1 (zh) |
PT (1) | PT673928E (zh) |
RU (1) | RU2143425C1 (zh) |
TW (1) | TW380138B (zh) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824690A (en) * | 1993-05-06 | 1998-10-20 | Hoechst Marion Roussel Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines |
US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
EP0714891A1 (en) * | 1994-11-22 | 1996-06-05 | Eli Lilly And Company | Heterocyclic tachykinin receptor antagonists |
FR2738245B1 (fr) * | 1995-08-28 | 1997-11-21 | Sanofi Sa | Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant |
FR2738819B1 (fr) | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
GB9521781D0 (en) * | 1995-10-24 | 1996-01-03 | Merck Sharp & Dohme | Therapeutic agents |
US6211199B1 (en) | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
ATE232858T1 (de) * | 1995-11-17 | 2003-03-15 | Aventis Pharma Inc | Substituierte 4-(1h-benzimidazol-2-yl- amino)piperidine zur behandlung allergischer erkrankungen |
RU2135494C1 (ru) * | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
US6423704B2 (en) | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
US6194406B1 (en) | 1995-12-20 | 2001-02-27 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease |
GB9600235D0 (en) * | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
GB9601697D0 (en) * | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
US5932571A (en) * | 1996-02-21 | 1999-08-03 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases |
US5922737A (en) * | 1996-02-21 | 1999-07-13 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases |
FR2745811B1 (fr) * | 1996-03-07 | 1998-05-22 | Sanofi Sa | Glutarimide disubstitue procede pour sa preparation, et son utilisation |
WO1998005640A2 (en) * | 1996-08-05 | 1998-02-12 | Smithkline Beecham S.P.A. | Process for the preparation of 3,3-disubstituted piperidines |
US6040316A (en) * | 1996-09-16 | 2000-03-21 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
AU4176997A (en) * | 1996-09-16 | 1998-04-02 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
US5789422A (en) * | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
US5977139A (en) * | 1996-12-15 | 1999-11-02 | Hoechst Marion Roussel, Inc. | Carboxysubstituted cyclic carboxamide derivatives |
US5861417A (en) * | 1996-12-19 | 1999-01-19 | Hoechst Marion Roussel, Inc. | Heterocyclic substituted pyrrolidine amide derivatives |
US6124319A (en) * | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
JP2001508798A (ja) * | 1997-01-21 | 2001-07-03 | メルク エンド カンパニー インコーポレーテッド | ケモカインレセプター活性のモジュレーターとしての3,3−二置換ピペリジン類 |
US6136827A (en) * | 1997-07-25 | 2000-10-24 | Merck & Co., Inc. | Cyclic amine modulations of chemokine receptor activity |
JP2002510327A (ja) * | 1997-07-25 | 2002-04-02 | メルク エンド カンパニー インコーポレーテッド | 環状アミンケモカイン受容体活性調節剤 |
US6140349A (en) * | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
JP2002501898A (ja) * | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
US6316445B1 (en) | 1998-05-15 | 2001-11-13 | Aventis Pharmaceuticals Inc. | Carboxy substituted acylic carboxamide derivatives |
FR2782082B3 (fr) * | 1998-08-05 | 2000-09-22 | Sanofi Sa | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
FR2784377B3 (fr) | 1998-10-09 | 2000-11-17 | Sanofi Sa | Nouveaux composes derives d'ureidopiperidine, antagonistes selectifs des recepteurs nk3 humains, procede pour leur obtention et compositions pharmaceutiques les contenant |
FR2787449B3 (fr) | 1998-12-15 | 2001-01-12 | Sanofi Sa | Derives de 3-phenyl-2,6-dioxopiperidin-3-yl propionamide et leur procede de preparation |
FR2787448B3 (fr) * | 1998-12-18 | 2001-01-12 | Sanofi Sa | Ester d'alkyle inferieur de l'acide 3-(3,4-dihalogenophenyl) -2,6-dioxopiperidine3-propionique et son mode de preparation |
FR2787790A1 (fr) * | 1998-12-23 | 2000-06-30 | Sanofi Sa | Procede de preparation du (r)-(+)-3-{1[2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl]-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates |
FR2792199B3 (fr) * | 1999-04-13 | 2001-05-18 | Sanofi Sa | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
GB9927125D0 (en) * | 1999-11-16 | 2000-01-12 | Univ Reading The | Placental human neurokinin B precursor |
AU2002219846A1 (en) * | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Novel use |
US6887889B2 (en) * | 2001-04-12 | 2005-05-03 | Pharmacopeia Drug Discovery, Inc. | Aryl and biaryl piperdines with MCH modulatory activity |
MY134211A (en) * | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
US20040152727A1 (en) * | 2001-05-18 | 2004-08-05 | Hay Douglas William Pierre | Novel use |
GB0208897D0 (en) * | 2002-04-18 | 2002-05-29 | Merck Sharp & Dohme | New method of treatment |
EP1501800A1 (en) * | 2002-05-03 | 2005-02-02 | Warner-Lambert Company LLC | Bombesin antagonists |
NZ544244A (en) * | 2003-07-03 | 2008-10-31 | Hoffmann La Roche | Dual NK1/NK3 antagonists for treating schizophrenia |
US7834008B2 (en) | 2003-08-15 | 2010-11-16 | H. Lundbeck A/S | Cyclopropyl derivatives as NK3 receptor antagonists |
KR20060066721A (ko) * | 2003-08-15 | 2006-06-16 | 하. 룬트벡 아크티에 셀스카브 | Nk3 수용체 길항제로서의 시클로프로필 유도체 |
GB0513747D0 (en) * | 2005-07-06 | 2005-08-10 | Merck Sharp & Dohme | Therapeutic compounds |
TW201018662A (en) * | 2005-12-12 | 2010-05-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
KR20120034774A (ko) * | 2006-07-20 | 2012-04-12 | 노파르티스 아게 | Cετρ 억제제로서의 아미노-피페리딘 유도체 |
EP2178534A4 (en) | 2007-07-17 | 2011-03-30 | Merck Sharp & Dohme | SOLUBLE EPOXY HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCESSING METHODS |
WO2014170648A1 (en) | 2013-04-19 | 2014-10-23 | Astrazeneca Ab | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
EP3704271A4 (en) | 2017-11-02 | 2021-09-08 | California Institute of Technology | NEUROKININ ANTAGONISTS AND RELATED USES |
CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0474561A1 (fr) * | 1990-09-05 | 1992-03-11 | Sanofi | Arylalkylamines, procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0512901A1 (fr) * | 1991-05-03 | 1992-11-11 | Sanofi | Composés polycycliques aminés et leurs énantiomères, procédé pour leur préparation et compositions pharmaceutiques en contenant |
WO1993018002A1 (fr) * | 1992-03-03 | 1993-09-16 | Elf Sanofi | Sels quaternaires de piperidines 4-substitues, leur preparation et compositions pharmaceutiques les contenant |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2676053B1 (fr) * | 1991-05-03 | 1993-08-27 | Sanofi Elf | Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
GB9321557D0 (en) * | 1992-11-03 | 1993-12-08 | Zeneca Ltd | Carboxamide derivatives |
GB9310713D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
EP0714891A1 (en) * | 1994-11-22 | 1996-06-05 | Eli Lilly And Company | Heterocyclic tachykinin receptor antagonists |
-
1995
- 1995-01-19 FR FR9500571A patent/FR2719311B1/fr not_active Expired - Fee Related
- 1995-03-16 NZ NZ270727A patent/NZ270727A/en not_active IP Right Cessation
- 1995-03-16 PL PL95307723A patent/PL185075B1/pl not_active IP Right Cessation
- 1995-03-17 DE DE69522355T patent/DE69522355T2/de not_active Expired - Lifetime
- 1995-03-17 DK DK95400590T patent/DK0673928T3/da active
- 1995-03-17 FI FI951265A patent/FI116621B/fi active IP Right Grant
- 1995-03-17 EP EP95400590A patent/EP0673928B1/fr not_active Expired - Lifetime
- 1995-03-17 AU AU14909/95A patent/AU693845B2/en not_active Ceased
- 1995-03-17 AT AT95400590T patent/ATE204863T1/de not_active IP Right Cessation
- 1995-03-17 IL IL11302695A patent/IL113026A/xx not_active IP Right Cessation
- 1995-03-17 ES ES95400590T patent/ES2164746T3/es not_active Expired - Lifetime
- 1995-03-17 HU HU9500806A patent/HUT72065A/hu unknown
- 1995-03-17 NO NO951044A patent/NO302944B1/no not_active IP Right Cessation
- 1995-03-17 PT PT95400590T patent/PT673928E/pt unknown
- 1995-03-17 RU RU95103737/04A patent/RU2143425C1/ru active
- 1995-03-17 CN CN95103542A patent/CN1056605C/zh not_active Expired - Fee Related
- 1995-03-18 TW TW084102614A patent/TW380138B/zh not_active IP Right Cessation
- 1995-03-18 KR KR1019950005722A patent/KR100238343B1/ko not_active IP Right Cessation
- 1995-03-20 CA CA002145000A patent/CA2145000C/en not_active Expired - Fee Related
- 1995-03-20 JP JP7061419A patent/JP2922816B2/ja not_active Expired - Fee Related
-
1996
- 1996-02-29 US US08/608,718 patent/US5942523A/en not_active Expired - Lifetime
- 1996-02-29 US US08/607,976 patent/US5741910A/en not_active Expired - Lifetime
-
1997
- 1997-11-04 NO NO975089A patent/NO303823B1/no not_active IP Right Cessation
-
1998
- 1998-05-19 HK HK98104342A patent/HK1005137A1/xx not_active IP Right Cessation
-
1999
- 1999-05-07 US US09/306,825 patent/US6124316A/en not_active Expired - Fee Related
-
2002
- 2002-05-15 CY CY0200032A patent/CY2278B1/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0474561A1 (fr) * | 1990-09-05 | 1992-03-11 | Sanofi | Arylalkylamines, procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0512901A1 (fr) * | 1991-05-03 | 1992-11-11 | Sanofi | Composés polycycliques aminés et leurs énantiomères, procédé pour leur préparation et compositions pharmaceutiques en contenant |
WO1993018002A1 (fr) * | 1992-03-03 | 1993-09-16 | Elf Sanofi | Sels quaternaires de piperidines 4-substitues, leur preparation et compositions pharmaceutiques les contenant |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1056605C (zh) | 作为人速激肽ⅲ受体的选择性拮抗剂的化合物及其用途 | |
CN1179954C (zh) | 取代的杂环化合物、其制备方法和含有这些化合物的药物组合物 | |
CN1146540C (zh) | 具有镇痛作用的新化合物及其用途 | |
CN1207283C (zh) | 4-氨基哌啶衍生物和它们作为药物的用途 | |
CN1304382C (zh) | 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂 | |
CN1144791C (zh) | 三唑化合物及其作为多巴胺d3配体的应用 | |
CN1198613C (zh) | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 | |
CN1046268C (zh) | 二氢吲哚-2-酮衍生物 | |
CN1142910C (zh) | 酰胺化合物 | |
CN1118595A (zh) | 氨茴酸衍生物 | |
CN1639147A (zh) | 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮类化合物的合成 | |
CN1910157A (zh) | 对受体cbi有亲和性的n′-(1,5-二苯基-1h-吡唑-3-基)磺酰胺衍生物 | |
CN1183770A (zh) | 哌嗪衍生物,含该化合物的药物,其用途以及制法 | |
CN1288464A (zh) | 作为orl-1受体激动剂的4-(2-酮-1-苯并咪唑啉基)哌啶化合物 | |
CN1471536A (zh) | 趋化因子受体拮抗剂及其使用方法 | |
CN1675203A (zh) | 取代的1-哌嗪酰基哌啶衍生物,它们的制备方法和治疗用途 | |
CN1152879C (zh) | 萘啶衍生物 | |
CN1064273A (zh) | 新的具有ngf生成促进活性的苯衍生物 | |
CN1030450C (zh) | 镇痛羧酸酰胺衍生物的制备方法 | |
CN1589261A (zh) | 哌啶衍生物及其作为趋化因子受体(尤其是ccr5)活性调节剂的用途 | |
CN1571781A (zh) | 4-咪唑啉-2-酮化合物 | |
CN1273463C (zh) | (1-苯甲酰甲基-3-苯基-3-哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物 | |
CN1245500A (zh) | 新型萘啶衍生物 | |
CN1585757A (zh) | 作为组织蛋白酶s抑制剂的寡肽以及含有它们的组合物 | |
CN1829689A (zh) | 苯甲胺衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
COR | Change of bibliographic data |
Free format text: CORRECT: PATENTEE; FROM: SANOFI CORP. TO: SANOFI SYNTHESIZING LABORATORY |
|
CP01 | Change in the name or title of a patent holder |
Patentee after: Sanofi Synthesis Lab. Patentee before: Sanofi |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SANOFI. AVENTIS CO., LTD. Free format text: FORMER NAME OR ADDRESS: SANOFI SYNTHESIZING LABORATORY |
|
CP01 | Change in the name or title of a patent holder |
Address after: France Patentee after: Sanofi Aventis Address before: France Patentee before: Sanofi Synthesis Lab. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20000920 Termination date: 20100317 |